• Biomolecules & Therapeutics
• /
• 제8권4호
• /
• pp.318-324
• /
• 2000

We have examined inhibitory erects on gasritis using omeprazole-cholestyramine resinate, which has been developed to increase the stability of omeprazole, the well-known proton pump inhibitor, in an acidic condition. To test the pharmacological action of this, we investigated the effect of omeprazole-cholestyramine resinate on indomethacin-induced gastritis in rats. Omeprazole was used as a reference drug. Orally administered omeprazole-cholestyramine resinate inhibited the indomethacin-induced gastritis in a dose-dependent manner. The inhibitory effect of omeprazole-cholestyramine resinate on the gastritis was similar to that of reference drug. In addition, rectal adminstration of the omeprazole-cholestyramine resinate inhibited the indomethacin-induced gastritis in a dose-dependent manner. The inhibitory effect of omeprazole-cholestyramine resinate was equipotent to reference drug. The basal gastric acid secretion was decreased when it was administered either orally or rectally. This inhibition of omfprazole-cholestyramine resinate was similar to that of omeprazole. These data suggest that omeprazole-cholestyramine resinate inhibit the gastritis in rats, and are comparable to omeprazole available in market.

• Journal of Pharmaceutical Investigation
• /
• 제18권3호
• /
• pp.133-137
• /
• 1988

In vitro studies were performed on the interaction of indomethacin with cholestyramine, a hypocholesterolemic substance. Cholestyramine showed a marked affinity for indomethacin among tested acidic drugs and the intensity of adsorption was dependent on pH, temperature and sodium chloride. Moreover, the combination of indomethacin with some acidic drugs that formed complexes with cholestyramine, considerably inhibited the adsorption of indomethacin on the resin.

• 한국식품영양과학회지
• /
• 제25권6호
• /
• pp.958-962
• /
• 1996

해조류인 참도박으로 부터 고지혈증 개선효과를 관찰하기 위하여 고지혈증을 유발시킨 흰쥐에 메탄올 추출물을 투여하고 혈액 및 간조직에서의 지방 함량을 측정하였다. 그 결과 참도박의 메탄올 추출물의 투여는 지방조직의 무게는 정상군에는 미치지 않으나 대조군에 비해 다소 감소하는 경향을 보였다. 고지방식이로 인위적으로 고지혈증을 유발시켰을때 정상군보다 total cholesterol, LDL-cholestero의 함량이 증가되던 것이 추출물의 투여로 total cholesterol의 함량이 현저히 감소되었으나 LDL-cholesterolt의 함량은 별다른 영향이 없었다. 또한 이들의 고지방식이군 보다 total lipid, triglyceride의 함량도 감소시켰다.

• 약학회지
• /
• 제38권3호
• /
• pp.250-264
• /
• 1994

Omeprazole(OMZ)-cholestyramine(CHL) and various OMZ-Dowex resin complexes were prepared by reaction between OMZ and activated resins in 0.1N NaOH solution. And their physical properties were tested by means of infrared(IR), differential scaning caloimeter(DSC), X-ray diffraction. Chemical stability of OMZ-CHL was increased markedly compared with OMZ and the decomposition of OMZ-CHL followed the pseudo first-order kinetics and the rate constants were $2.743{\times}10^{-4}/day$ at $20^{\circ}C$, $7.83{\times}10^{-3}day^{-1}$ under 80% RH and $1.68{\times}10^{-2}day^{-1}$ under UV radiation, respectively. On the other hand, the rate constants of OMZ were $2.996{\times}10^{-4}day^{-1}$ at $20^{\circ}C$, $1.17{\times}10^{-2}day^{-1}$ under 85% RH, and $4.07{\times}10^{-2}day^{-1}$ under UV radiation, respectively. The rates of dissolution of OMZ-CHL bulk and OMZ-CHL tablet were 100% and more than 85% in 15 minutes, respectively, which were increased than OMZ base and OMZ-tablet. In the acute toxicological test, the value of oral $LD_{50}$(mouse) was 4.608 g/kg. OMZ-CHL was pelletized using lactose, polyethyle neglycol(PEG), D-sorbitol, Avicel PH 101, sodium laurylsulfate and polyvinylpyrrolidone(PVP) K-30, and enteric coated with HPMCP, Myvacet, acetone, ethanol and cetanol, of which dissolution rate was found to be more than 85% in 10 minutes. From the above results, it was found that OMZ-CHL is a useful means for development of new oral dosage forms of OMZ.

• Clinical Endoscopy
• /
• 제56권2호
• /
• pp.194-202
• /
• 2023

Background/Aims: Endoscopic therapy for neoplastic Barrett's esophagus (BE) has become the standard of care over the past two decades. In clinical practice, we regularly encounter patients who fail to achieve complete squamous epithelialization of the esophagus. Although the therapeutic strategies in the individual stages of BE, dysplasia, and esophageal adenocarcinoma are well studied and largely standardized, the problem of inadequate healing after endoscopic therapy is only marginally considered. This study aimed to shed light on the variables influencing inadequate wound healing after endoscopic therapy and the effect of bile acid sequestrants (BAS) on healing. Methods: Retrospective analysis of endoscopically treated neoplastic BE in a single referral center. Results: In 12.1% out of 627 patients, insufficient healing was present 8 to 12 weeks after previous endoscopic therapy. The average follow-up duration was 38.8±18.4 months. Complete healing was achieved in 13 patients already after intensifying proton pump inhibitor therapy. Out of 48 patients under BAS, 29 patients (60.4%) showed complete healing. An additional eight patients (16.7%) improved, but only partial healing was achieved. Eleven (22.9%) patients showed no response to BAS augmented therapy. Conclusions: In cases of insufficient healing even under exhaustion of proton pump inhibitors, treatment with BAS can be an option as an ultimate healing attempt.